Contact
searchSearch
HMP Global
Login

BCMA News

News
Subgroup of Patients With MM Show Lower T-Cell Count Against COVID-19
12/01/2021
A subgroup of patients with MM who received anti-BCMA or anti-CD38 therapies were found to have lower B and T-cell counts against SARS-CoV-2.
A subgroup of patients with MM who received anti-BCMA or anti-CD38 therapies were found to have lower B and T-cell counts against SARS-CoV-2.
A subgroup of patients with MM...
12/01/2021
Oncology
News
Low Dose GSI, BCMA CAR T-Cell Combo Yields Anti-Tumor Activity in R/R MM
11/10/2021
GSI combined with BCMA CAR T-cell treatment was shown to create deep, tolerable, and durable responses in patients with R/R MM; all data were presented at the 2021 ASH Meeting.
GSI combined with BCMA CAR T-cell treatment was shown to create deep, tolerable, and durable responses in patients with R/R MM; all data were presented at the 2021 ASH Meeting.
GSI combined with BCMA CAR...
11/10/2021
Oncology
News
Anti-BCMA CAR-T Cell Therapy Found Safe, Effective in Extramedullary MM
10/21/2021
Two phase 1 studies investigate the safety and efficacy of anti-BCMA CAR-T cell therapy for R/R patients with or without extramedullary MM and identify important risk factors.
Two phase 1 studies investigate the safety and efficacy of anti-BCMA CAR-T cell therapy for R/R patients with or without extramedullary MM and identify important risk factors.
Two phase 1 studies investigate...
10/21/2021
Oncology
News
Immune Deficiencies Present Following Anti-BCMA CAR-T Cell Therapy in R/R MM
10/04/2021
Researchers investigated recovery durations of patients with R/R multiple myeloma who received BCMA CAR-T cell therapy. Results confirm immune and hematologic deficiencies after treatment.
Researchers investigated recovery durations of patients with R/R multiple myeloma who received BCMA CAR-T cell therapy. Results confirm immune and hematologic deficiencies after treatment.
Researchers investigated...
10/04/2021
Oncology
News
Teclistamab Shows Potential Activity in BCMA-Positive MM
09/30/2020
Data support further examination of teclistamab therapy in the context of patients with MM and BCMA expression.
Data support further examination of teclistamab therapy in the context of patients with MM and BCMA expression.
Data support further examination...
09/30/2020
Oncology
News
Combined Anti-CD19 and Anti-BCMA CAR-T Therapy Feasible for Relapsed/Refractory MM
08/14/2019
The combined use of humanized anti-CD19 and anti-BCMA CAR T-cells is feasible for patients with relapsed or refractory multiple myeloma.
The combined use of humanized anti-CD19 and anti-BCMA CAR T-cells is feasible for patients with relapsed or refractory multiple myeloma.
The combined use of humanized...
08/14/2019
Oncology
News
New CAR-T Therapy Less Toxic, More Effective for MM Than Other CAR-Ts
11/29/2018
P-BCMA-101, a novel CAR-T therapy, has demonstrated significant efficacy in patients with relapsed or refractory MM.
P-BCMA-101, a novel CAR-T therapy, has demonstrated significant efficacy in patients with relapsed or refractory MM.
P-BCMA-101, a novel CAR-T...
11/29/2018
Oncology
News
Novel CAR-T Drug Promising in Relapsed or Refractory MM
09/11/2018
A new stem cell memory CAR-T therapy has demonstrated exceptional efficacy and safety in patients with relapsed and/or refractory multiple myeloma.
A new stem cell memory CAR-T therapy has demonstrated exceptional efficacy and safety in patients with relapsed and/or refractory multiple myeloma.
A new stem cell memory CAR-T...
09/11/2018
Oncology
News
CAR T-Cells Targeting BCMA Improve Outcomes in MM
03/27/2018
Multiple studies have demonstrated positive results for CAR T-cells in treating relapsed and refractory MM.
Multiple studies have demonstrated positive results for CAR T-cells in treating relapsed and refractory MM.
Multiple studies have...
03/27/2018
Oncology

Recent News

News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use